​

Biogen (BIIB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIIB Stock Forecast

Biogen (BIIB) stock forecast, based on 33 Wall Street analysts, predicts a 12-month average price target of $242.33, with a high of $315.00 and a low of $180.00. This represents a 67.81% increase from the last price of $144.41.

$100 $150 $200 $250 $300 $350 High: $315 Avg: $242.33 Low: $180 Last Closed Price: $144.41

BIIB Stock Rating

Biogen stock's rating consensus is Buy, based on 33 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (66.67%), 11 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 33 11 22 0 Strong Sell Sell Hold Buy Strong Buy

BIIB Forecast vs Benchmarks

TypeNameUpside
StockBiogen67.81%
SectorHealthcare Stocks 25.20%
IndustryDrug Manufacturers - General Stocks22.62%

Price Target Trends

1M3M12M
# Anlaysts-625
Avg Price Target-$257.33$272.92
Last Closing Price$144.41$144.41$144.41
Upside/Downside-78.19%88.99%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2561416--36
Dec, 2471515--37
Nov, 2491614--39
Oct, 2491611--36
Sep, 2491612--37
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 09, 2024Michael YeeJefferies$180.00$157.7814.08%24.65%
Nov 15, 2024Brian SkorneyRobert W. Baird$300.00$162.8384.24%107.74%
Oct 31, 2024Jay OlsonOppenheimer$255.00$181.1840.74%76.58%
Oct 31, 2024Terence FlynnMorgan Stanley$204.00$181.1812.60%41.26%
Oct 30, 2024Christopher RaymondRaymond James$315.00$181.1873.86%118.13%
Oct 30, 2024Salveen RichterGoldman Sachs$290.00$181.1860.06%100.82%
Oct 17, 2024Evan SeigermanBMO Capital$230.00$188.1722.23%59.27%
Oct 03, 2024Ashwani VermaUBS$202.00$188.747.03%39.88%
Sep 23, 2024Laura ChicoWedbush$205.00$199.362.83%41.96%
Jul 29, 2024Brian SkorneyRobert W. Baird$294.00$212.7038.22%103.59%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 02, 2025Piper SandlerOverweightNeutraldowngrade
Dec 09, 2024JefferiesBuyHolddowngrade
Nov 13, 2024CitigroupNeutralNeutralinitialise
Oct 31, 2024OppenheimerOutperformOutperformhold
Oct 31, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Oct 30, 2024Piper SandlerOverweightOverweighthold
Oct 30, 2024Goldman SachsBuyBuyhold
Oct 17, 2024BMO CapitalOutperformOutperformhold
Oct 03, 2024UBSNeutralNeutralhold
Sep 24, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$0 $30 $60 $90 $120 $150 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.86$10.44$20.96$144.70-----
Avg Forecast$33.79$19.19$17.11$14.99$16.42$16.48$17.37$18.95$20.72
High Forecast$31.69$18.00$15.76$14.74$16.13$14.45$13.83$15.13$18.61
Low Forecast$36.21$20.57$18.68$15.57$17.18$20.03$25.69$26.87$23.62
Surprise %-26.43%-45.60%22.50%865.31%-----

Revenue Forecast

$9B $10B $11B $12B $13B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$13.44B$10.98B$10.17B$9.84B-----
Avg Forecast$13.38B$10.87B$10.07B$9.93B$9.63B$9.43B$9.56B$9.92B$10.14B
High Forecast$12.74B$10.35B$9.46B$9.78B$9.55B$8.69B$9.56B$9.89B$9.35B
Low Forecast$14.12B$11.47B$10.78B$10.08B$9.74B$10.42B$9.57B$9.94B$11.23B
Surprise %0.48%1.01%1.00%-0.93%-----

Net Income Forecast

$500M $1B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.00B$1.56B$3.05B$1.16B-----
Avg Forecast$3.27B$1.37B$1.82B$1.16B$2.42B$2.51B$2.37B$2.56B$3.02B
High Forecast$2.61B$1.09B$1.46B$928.88M$2.35B$2.10B$2.01B$2.20B$2.71B
Low Forecast$3.92B$1.64B$2.18B$1.39B$2.50B$2.92B$3.74B$3.91B$3.44B
Surprise %22.39%13.84%67.40%------

BIIB Forecast FAQ

Is Biogen stock a buy?

Biogen stock has a consensus rating of Buy, based on 33 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Biogen is a favorable investment for most analysts.

What is Biogen's price target?

Biogen's price target, set by 33 Wall Street analysts, averages $242.33 over the next 12 months. The price target range spans from $180 at the low end to $315 at the high end, suggesting a potential 67.81% change from the previous close price of $144.41.

How does Biogen stock forecast compare to the average forecast of its sector, industry, and investment themes?

Biogen stock forecast shows a 67.81% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the drug manufacturers - general stocks industry (22.62%).

What is the breakdown of analyst ratings for Biogen over the past three months?

  • January 2025: 16.67% Strong Buy, 38.89% Buy, 44.44% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 18.92% Strong Buy, 40.54% Buy, 40.54% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 23.08% Strong Buy, 41.03% Buy, 35.90% Hold, 0% Sell, 0% Strong Sell.

What is Biogen’s EPS forecast?

Biogen's average annual EPS forecast for its fiscal year ending in December is 16.42 for 2024, a -88.65% decrease from the reported $144.7 in 2023. The prediction for 2025 is $16.48, $17.37 for 2026, $18.95 for 2027, and $20.72 for 2028.

What is Biogen’s revenue forecast?

Biogen's average annual revenue forecast for its fiscal year ending in December is $9.63B for 2024, a -2.04% decrease from the reported $9.84B in 2023. The forecast for 2025 is $9.43B, $9.56B for 2026, $9.92B for 2027, and $10.14B for 2028.

What is Biogen’s net income forecast?

For its fiscal year ending in December, Biogen's average annual net income forecast is $2.42B for 2024, reflecting an 108.85% increase from the reported $1.16B in 2023. The projection for 2025 is $2.51B, $2.37B for 2026, $2.56B for 2027, and $3.02B for 2028.